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BRIEF DEFINITIVE REPORT
To be recognized by T lymphocytes, protein 
antigens must be converted into short peptides 
bound to MHC molecules, which are displayed 
on the surface of APCs. The ability of APCs to 
generate peptide–MHC complexes is, there-
fore, essential to the initiation of the immune 
response (1, 2). Although the interaction be-
tween peptides and MHC class II molecules 
and the ability of the T cell repertoire to gener-
ate antigen receptors of cognate specifi  city have 
been extensively studied, it remains diffi   cult to 
predict or to manipulate the extraction of pep-
tide ligands from protein antigens (3, 4). As a 
consequence, the diff  erences in immunogenic-
ity between protein antigens are poorly under-
stood and, therefore, approaches to induce 
antigen-specifi   c immunity remain largely 
  empirical (5, 6).
Antigenic peptides are produced by lyso-
somal proteolysis, and, thus, effi   cient lysosomal 
degradation is often assumed to favor production 
of ligands for MHC class II molecules. This no-
tion derives mostly from in vitro experiments. 
For instance, blocking lysosomal function with 
protease or acidifi  cation inhibitors decreased an-
tigen presentation (7–11).   Enhancing lysosomal 
proteolysis by the presence of protease-specifi  c 
cleavage sites (12) or by destabilizing proteins 
also favored presentation to T cell hybridomas 
(13–15). However, these in vitro studies did 
not evaluate the role of lysosomal proteolysis 
on immunogenicity in vivo.
We decided to take a direct and physiologi-
cal approach to investigating the relationship 
between antigen proteolysis and immunity in 
vivo. We chose not to use pharmacological or 
genetic approaches that could potentially have 
multiple eff  ects on APCs. We studied instead 
the immunogenicity of proteins with the same 
sequence (same T cell epitopes) and structure 
(same B cell epitopes) but with diff  erent suscep-
tibilities to lysosomal proteolysis. We found that 
less digestible forms of otherwise identical an-
tigens are more immunogenic, inducing more 
effi   cient T cell priming and antibody responses.
RESULTS AND DISCUSSION
We began by comparing bovine pancreatic 
  ribonuclease (RNase-A), a compact stable 
  protein, with its variant RNase-S, in which a 
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single peptide bond is cleaved (between Ala20 and Ser21) 
(16, 17). Although both RNase-A and RNase-S are other-
wise structurally and enzymatically identical (16, 17) (Fig. 1 A), 
RNase-S was far more susceptible to lysosomal proteolysis 
both in vitro by lysosomal extracts and after internalization by 
bone marrow–derived DCs (BM-DCs); this diff  erence was 
maintained after antigen adsorption onto an adjuvant such as 
aluminum hydroxide (Alum; Fig. 1, B and C). We next asked 
if the diff  erential susceptibilities to proteolysis of these model 
antigens aff  ected their capacity to induce IgG responses as a 
physiological in vivo measure of their ability to be presented 
on MHC class II molecules and to prime CD4+ T cells in 
vivo. After injecting each of the proteins adsorbed onto Alum 
into mice, the stable form of RNase (RNase-A) was found to 
induce much higher (>10,000-fold) IgG titers than did the 
unstable form (RNase-S; Fig. 2 A).
We next examined antigen uptake by APCs in vivo by 
FACS analysis. DCs in the draining lymph nodes contained 
comparable amounts of RNase-A and RNase-S 2.5 h after 
intradermal injection (Fig. 1 D). Moreover, diff  erential anti-
body responses were also observed when BM-DCs loaded ex 
vivo with the same amount of RNase-A or RNase-S were 
adoptively transferred into naive recipient mice (Fig. 2 D). 
Collectively these results rule out that the diff  erences in im-
munogenicity between the two proteins could result from 
diff  erential access to APCs.
That both forms of RNase indeed share the same B cell 
epitopes was further emphasized by the fact that the small 
amount of anti-RNase IgG elicited after injection of high 
doses of RNase-S also reacted with RNase-A, and vice versa 
(unpublished data). Moreover, both forms of RNase induced 
comparable soluble IgM responses (2–4-fold diff  erence, as 
opposed to >10,000-fold diff  erence in IgG responses; Fig. 2, 
A and C). This indicated that, despite being recognized simi-
larly by B cells, RNase-S was not adequately presented to 
CD4+ T cells.
To further show that the rapid lysosomal degradation of 
RNase-S limited MHC class II presentation and T cell prim-
ing in vivo, we analyzed the antibody responses to defi  ned B 
cell epitopes introduced on RNase-A or RNase-S. The IgG 
responses to haptens such as FITC and DNP were strong 
only when they were coupled to the stable protein carrier 
(RNase-A; Fig. 2 B and not depicted). When low doses of 
antigens were injected with stronger adjuvants (incomplete 
or complete Freund’s), RNase-S was still less immunogenic 
than RNase-A (unpublished data). The diff  erences in im-
munogenicity of the model antigens were maintained over 
a broad dose range (1–1,000 μg) and after multiple injec-
tions of antigen (unpublished data), emphasizing that the 
diff  erent immunogenicity of RNase-A and RNase-S most 
likely refl  ects their effi   ciency of presentation on MHC class 
II molecules.
Figure 1.  Differential susceptibility of RNase-A and RNase-S to 
lysosomal proteolysis. (A) RNase-A, RNase-S, and their FITC derivatives 
have the same ribonuclease activity, indicating that attachment of FITC 
and subtilisin cleavage had no major effect on their three-dimensional 
structures. (B) SDS-PAGE analysis of the degradation of RNase-A and 
RNase-S, soluble or adsorbed onto Alum, by lysosomal extracts of 
BM-DCs at 37°C for the indicated times. (C) BM-DCs were pulsed with 
0.5 mg/ml FITC–RNase-A or FITC–RNase-S (soluble or adsorbed onto 
Alum) for 1 h at 37°C, washed, and then further cultured for the indi-
cated times. The percentage of degradation of antigen represents the 
percentage of FITC+ CD11c+ cells at the indicated time subtracted to the 
percentage FITC+ CD11c+ cells at 0 h. (D) Persistence of the stable form 
(RNase-A) in lymph node DCs. Mice were co-injected intradermally with 
20 μg of Alexa 488–RNase-A and 20 μg of Alexa 647–RNase-S. Single 
cell suspensions were prepared from the draining lymph nodes, removed 
2.5 or 16 h after injection, stained with anti-CD11c–PE, and analyzed by 
FACS. The histograms depict CD11c+ populations scored for their content 
of Alexa 488–RNase-A or Alexa 647–RNase-S 2.5 (black line) and 16 
(gray line) h after injection. The dashed gray line depicts CD11c+ cells 
from noninjected control mice.JEM VOL. 203, September 4, 2006  2051
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Indeed, cellular immune responses were also stronger to 
the antigen more resistant to lysosomal proteolysis (RNase-A). 
Primarily, immunization with RNase-A but not RNase-S 
elicited robust T cell recall responses in vitro (Fig. 2, E and F). 
Also, the delayed-type hypersensitivity response in mice 
  immunized with the stable form (RNase-A) was substantial, 
whereas it was undetectable in mice immunized with RNase-S 
(Fig. 2 G). In addition, the IgG responses to RNase-A and to 
FITC coupled to RNase-A exhibited the hallmarks of con-
ventional CD4-dependent T cell responses, as no anti-RNase 
or anti-FITC IgGs were detected in CD4- or MHC class 
II–defi  cient mice (Fig. 3 A). The same diff  erence in immuno-
genicity between RNase-A and RNase-S was observed in 
diff  erent mouse strains (Fig. 3 B), indicating that the increased 
immunogenicity of RNase-A was not associated with indi-
vidual MHC class II haplotypes. Similarly, the diff  erential 
immunogenicity of RNase-A and RNase-S was independent 
of the route of injection (intraperitoneal, intradermal, or in-
tramuscular; Fig. 2 A and Fig. 3 C) and, consequently, of the 
population of APCs that initially encounter the antigens.
We extended the analysis to another antigen with a dif-
ferent structure and T cell epitopes. For this purpose, we 
compared the immunogenicity of horseradish peroxidase 
(HRP) and its variant apo-HRP, from which the calcium 
and heme group have been removed, leaving the intact but 
destabilized polypeptide chain of HRP. Both forms of HRP 
have the same amino acid sequence and were not covalently 
modifi  ed; therefore, they possess the same T cell epitopes. 
They also retain intact their four intramolecular disulfi  de 
bonds, maintaining similar three-dimensional structures and 
antigenicity, as refl  ected by the fact that polyclonal antibodies 
from several species recognized HRP and apo-HRP identi-
cally under native conditions (Fig. 4 A). However, the two 
forms of HRP, soluble or adsorbed onto Alum, diff  ered 
markedly in their susceptibility to lysosomal proteolysis, with 
apo-HRP being more readily digested by DC lysosomal pro-
teases in vitro and ex vivo after internalization by BM-DCs 
(Fig. 4, B and C).
Immunization experiments in mice showed essentially 
the same pattern of immunogenicity as with stable and unsta-
ble forms of RNase: the stable form of HRP (intact HRP) 
induced stronger T cell priming (Fig. 4, D and E) and IgG 
responses (Fig. 4 F) than the unstable form (apo-HRP). Simi-
larly, the IgG responses to a hapten (FITC) were more robust 
when it was presented on the protein backbone of the stable 
form (HRP; Fig. 4 G). As with RNase, these diff  erences 
were maintained over a 1,000-fold dose range (unpublished 
data). Both forms of HRP also produced similar soluble IgM 
responses (Fig. 4 H), and all antisera raised against HRP fully 
recognized apo-HRP (unpublished data), indicating that 
Figure 2.  Differential susceptibility of RNase-A and RNase-S to 
lysosomal proteolysis affects their immunogenicity. (A–D) The stable 
form (RNase-A) induces stronger IgG responses than the unstable form 
(RNase-S). Mice were immunized by intraperitoneal injection of the indi-
cated doses of a mixture of RNase-A and FITC–RNase-A or RNase-S and 
FITC–RNase-S adsorbed onto Alum twice at 2-wk intervals. 10 d after the 
last injection, the sera were collected and IgG anti–RNase-A (A), IgG anti-
FITC (B), and IgM anti–RNase-A (C) were titrated by ELISA. (D) C57BL/6 
mice were immunized by a single injection in the footpad of BM-DCs 
loaded with FITC–RNase-A or FITC–RNase-S. 10 d later, the sera were col-
lected, and IgG anti-FITC was titrated by ELISA. The horizontal lines repre-
sent the mean value of each group. N.D., none detected. (E and F) The 
protease-resistant form (RNase-A) induces a stronger priming of cellular 
immune responses than the form more readily degraded (RNase-S). Spleno-
cytes from mice previously immunized with RNase-A (E) or RNase-S (F) 
were incubated with the indicated doses of antigens. T cell proliferation 
was estimated by [3H]thymidine incorporation 2 d later. (G) Delayed-type 
hypersensitivity response in mice immunized with the stable form 
(RNase-A) is higher than in mice immunized with the unstable form 
(RNase-S). Immunized mice were challenged by injection of 1 μg of 
RNase-A into one ear, while the other ear received PBS. The ear thickness 
was measured 24 h later.2052  LIMITING PROTEOLYSIS ENHANCES IMMUNOGENICITY | Delamarre et al.
both forms of HRP shared the same IgG epitopes, but that 
the rapidly degraded form was weakly immunogenic. If the 
poor priming of T cells by proteins that are rapidly degraded 
(RNase-S and apo-HRP) was primarily caused by enhanced 
susceptibility to lysosomal degradation, stabilizing them to 
proteolysis should enhance their capacity to induce IgG re-
sponses. To test this possibility, we generated inter- and in-
tramolecular cross-linked forms of RNase-S or apo-HRP by 
fi  xation with aldehydes (18, 19), resulting in molecules that 
became more resistant to lysosomal proteolysis in vitro (Fig. 
5 A and Fig. S1 A, available at http://www.jem.org/cgi/
content/full/jem.20052442/DC1). The stabilization to lyso-
somal proteolysis of RNase-S and apo-HRP by fi  xation was 
also observed in intact cells after internalization into BM-
DCs (Fig. 5 B and Fig. S1 B). In both cases, aldehyde-medi-
ated stabilization largely restored the ability of these otherwise 
poorly immunogenic proteins to induce IgG responses to 
RNase (Fig. 5 C) and HRP (Fig. 5 E), as well as to coupled 
haptens (FITC; Fig. 5, D and F).
One contributing factor to the increased ability of more 
stable antigens to elicit immune responses is that the restricted 
susceptibility to lysosomal proteolysis favored the production 
of peptide–MHC class II complexes by DCs, at least in vitro 
(Fig. 2 E and Fig. 4 D). In addition, and just as important in 
an in vivo setting, we found that the increased stability to ly-
sosomal proteolysis also favored the retention of antigens 
captured by DCs to lymphoid organs. 16 h after a single in-
tradermal injection, the stable forms of RNase (Alexa 488–
RNase-A) could be detected in CD11c+ DCs in the draining 
lymph nodes (Fig. 1 D). In contrast, the rapidly degraded 
form (Alexa 647–RNase-S) was barely detectable under the 
same conditions (Fig. 1 D). Combined with the fact that dif-
ferential immunogenicity was observed by adoptively trans-
ferring DCs containing either RNase-A or RNase-S (Fig. 2 D), 
these results strongly suggest that at least one eff  ect of de-
creased susceptibility to proteolysis is to facilitate intracellular 
antigen survival in DCs, which would allow for a sustained 
provision of MHC–peptide complexes.
Our fi  ndings show that, in contrast to a prevailing view 
derived mostly from in vitro experiments, the immunogenic-
ity of protein antigens in vivo can be enhanced by reducing 
their susceptibility to lysosomal proteolysis. This may there-
fore be an important factor contributing to the largely unex-
plained diff  erences among proteins in their abilities to elicit 
immune responses. Although this feature may vary for diff  er-
ent antigens, the fact that we have obtained identical results 
for two entirely unrelated proteins, and for haptens coupled 
to them, suggests that it represents a general principle. It is 
noteworthy that we did not fi  nd major diff  erences in the 
presentation of defi  ned epitopes from RNase-A and RNase-S 
to CD4+ T cell hybridomas in vitro (unpublished data), al-
though such diff  erences were observed in vivo and using 
primary T cells, emphasizing the importance of in vivo stud-
ies to examine protein immunogenicity. It would be interest-
ing to examine the impact of protein digestibility on the 
activation of naive versus memory T cells.
The susceptibility to lysosomal proteolysis may not only 
enhance the preservation of CD4+ T cell epitopes themselves 
but also clearly increases the persistence of the proteins from 
which those epitopes are extracted. DCs can take many hours 
or days to traverse from the periphery to lymphoid organs 
where they engage their cognate T cells to initiate immune 
responses (20); therefore, antigen persistence provides a 
source of antigen for sustained processing and presentation by 
DCs within (or en route to) secondary lymphoid organs (21, 
22) and, potentially, presentation of intact antigens to B cells 
(23, 24). Although the production of peptide–MHC class II 
complexes from a given antigen may not always be favored 
by restricting digestion, the enhanced dissemination and per-
sistence of stable antigens (or antigens in APCs of restricted 
lysosomal proteolysis) should consistently contribute to im-
munogenicity. It is interesting to speculate that, as part of 
their mechanism of action, some adjuvants and carrier pro-
teins could act at least in part by protecting the antigens they 
carry against lysosomal destruction. For example, coupling 
peptides to large, poorly digestible carriers would in essence 
convert labile peptides into relatively stable proteins.
The susceptibility of exogenous antigens to lysosomal pro-
teolysis may also aff  ect their ability to elicit CD8+ T cell re-
sponses during cross-presentation. Less digestible antigens may 
have a greater chance of surviving the digestive environment 
inside lysosomes to gain access to the cystosol for presentation 
on MHC class I molecules. This in fact may contribute to the 
Figure 3.  The IgG responses to RNase are CD4+ T cell dependent, 
and the differential immunogenicity between RNase-A and RNase-S 
is independent of the mouse strain and the route of injection. 
CD4−/− and MHC class II−/− mice on the C57BL/6 background (A) and 
mice from the C3H/HeJ and B6D2F1 strains (B) were immunized by intra-
peritoneal injection of a mixture of RNase-A and FITC–RNase-A or RNase-S 
and FITC–RNase-S (1 μg each) adsorbed onto Alum twice at a 2-wk interval. 
10 d after the last injection, the sera were collected, and IgG anti-RNase 
and anti-FITC were titrated by ELISA. (C) Experiments shown as in A and B, 
except that C57BL/6 mice were immunized by intradermal or intramuscular 
injection of antigens. The horizontal lines represent the mean value of 
each group. N.D., none detected.JEM VOL. 203, September 4, 2006  2053
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enhancement of antigen cross-presentation observed in the 
presence of chloroquine (25). In addition, the comparative ef-
fi  ciency of DCs relative to macrophages in cross presentation 
(26) may at least in part refl  ect the relative ineffi   ciency with 
which DCs degrade endocytosed antigens (27).
Our results provide direct support for the concept that 
the limited proteolytic capacity of DCs plays an important 
role in vivo in augmenting their effi   ciency as APCs by en-
hancing not only peptide–MHC class II production but also 
antigen dissemination and persistence in vivo (27). This may 
have implications for vaccine design, particularly for the elic-
itation of MHC class II–dependent antibody responses. 
Chemical modifi  cations or the use of carriers that enhance 
antigen resistance to lysosomal proteolysis may enhance anti-
gen immunogenicity. This approach would capitalize on one 
of the key biological properties of DCs to further enhance 
their antigen-presenting functions.
MATERIALS AND METHODS
Mice and cells. C57BL/6, C3H/HeJ, and B6D2F1 mice were purchased 
from The Jackson Laboratory. CD4−/− and MHC class II−/− mice on the 
C57BL/6 background were purchased from Taconic. All mice were males 
and were used at 6–12 wk of age. The Institutional Animal Care and Use 
Committee at Yale University approved all animal protocols. BM-DCs were 
grown as previously described (28). Lysosomal extracts of DCs were pre-
pared as previously described (27).
Model antigens. RNase-A and RNase-S (Sigma-Aldrich) were character-
ized as previously described (29). Apo-HRP was prepared as previously de-
scribed (30). FITC (Sigma-Aldrich), Alexa 488, and Alexa 647 (Invitrogen) 
derivatives were prepared according to the manufacturer’s recommenda-
tions. For fi  xation with aldehydes, 2 mg/ml of antigens were incubated in 
Figure 4.  Limited lysosomal proteolysis of HRP results in enhanced 
immunogenicity. (A) HRP (H) and apo-HRP (a) give rise only to complete 
identity precipitation lines by gel immunodiffusion assay in the presence 
of anti-HRP sera (center well) raised in the indicated species, indicating 
that HRP and its derivative (apo-HRP) have the same antigenicity. 
(B) SDS-PAGE analysis of the degradation of HRP and apo-HRP, soluble or 
adsorbed onto Alum, by lysosomal extracts of BM-DCs at 37°C for the 
indicated times. (C) BM-DCs were pulsed with 0.5 mg/ml FITC-HRP or 
FITC–apo-HRP for 1 h at 37°C, washed, and then further cultured for the 
indicated times. The percentage of degradation of antigen represents the 
percentage of FITC+ CD11c+ cells at the indicated time, subtracted to 
the percentage FITC+ CD11c+ cells at 0 h. (D and E) The protease resistant 
form (HRP) is presented more effi  ciently to T cells than the form more 
readily degraded (apo-HRP). Splenocytes from mice previously immunized 
with HRP (D) or apo-HRP (E) were incubated with the indicated doses of 
antigens. After 2 d in culture, T cell proliferation was estimated by 
[3H]thymidine incorporation. (F–H) The stable form (HRP) induces stronger 
IgG responses than the unstable form (apo-HRP). Mice were immunized 
by intraperitoneal injection of the indicated doses of a mixture of HRP 
and FITC-HRP or apo-HRP and FITC–apo-HRP adsorbed onto Alum twice 
at a 2-wk interval. 10 d after the last injection, the sera were collected, 
and IgG anti-HRP (F), IgG anti-FITC (G), and IgM anti-HRP (H) were 
titrated by ELISA. The horizontal lines represent the mean value of each 
group. N.D., none detected.2054  LIMITING PROTEOLYSIS ENHANCES IMMUNOGENICITY | Delamarre et al.
PBS in the presence of 10 mM paraformaldehyde and 2 mM glutaraldehyde 
on ice for 30 min. Reactions were stopped by addition of 50 mM glycine, 
followed by a 10-min centrifugation at 10,000 g to remove aggregates and a 
subsequent desalting into PBS. Recognition of model antigens by polyclonal 
antibodies was conducted by ELISA or by immunodiff  usion in gels.
Immunizations. Mice were immunized by intraperitoneal, intradermal, or 
intramuscular injection of 1–1,000 μg of the diff  erent antigens adsorbed onto 
Alum adjuvant (Imject Alum; Pierce Chemical Co.) twice at a 2-wk interval. 
Alternatively, mice were immunized by a single injection with 300,000 
CD11c+ BM-DCs (loaded with 0.5 mg/ml of antigens for 2 h) in the footpad. 
Sera were collected before immunization and 10 d after the last injection.
ELISA. Sera were titrated by using plates (Maxisorp; Nunc) coated with 
RNase-A, HRP, or FITC-BSA (5 μg/ml each). Antibodies were detected 
using alkaline phosphatase–conjugated donkey antibodies against mouse 
IgM or IgG (Jackson ImmunoResearch Laboratories), as well as with 
4-methylumbelliferyl phosphate (Sigma-Aldrich).
Delayed-type hypersensitivity response. After immunization, the mice 
were challenged by injection of 1 μg of antigen into one ear, while the other 
ear received PBS. The ear thickness was measured 24 h later using a 
  micrometer (Ultra-Mic; Fowler).
In vitro degradation assays. Antigen degradation assays were done as 
previously described (27).
Ex vivo degradation assays. BM-DCs were loaded with 0.5 mg/ml of 
antigens for 1 h and incubated at 37°C for the times indicated in the fi  gures. 
The presence of the proteins and cell surface expression of CD11c were 
monitored by FACS.
In vivo degradation assays. Alexa 488–RNase-A and Alexa 647–
RNase-S (20 μg each) were simultaneously injected intradermally. At the 
times indicated in the fi  gures, the draining lymph nodes were removed, and 
cells were dissociated by treatment with Blendzyme 2 (Roche). The pres-
ence of the proteins and cell surface expression of CD11c were monitored 
by FACS.
Antigen processing and presentation assays. Splenocytes from immu-
nized mice were incubated with the doses of antigens indicated in the fi  gures 
for 48 h. T cell responses were evaluated by measuring T cell proliferation, 
as estimated by [3H]thymidine incorporation.
Online supplemental material. Fig. S1 shows that fi  xation of apo-HRP 
with aldehydes increases its resistance to lysosomal proteolysis in vitro and 
enhances its survival ex vivo. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20052442/DC1.
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